Trial Profile
Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care (CIC) - Electronic Measurement of Compliance.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2010
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Rosuvastatin (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Therapeutic Use
- Acronyms SCAVANCE
- Sponsors AstraZeneca
- 01 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Apr 2010 New trial record